| Literature DB >> 34227302 |
Dapeng Li1, Guangshan Xie1, Peisi Xie1, Lin Zhu1, Zongwei Cai1.
Abstract
Protein glycosylation is a ubiquitous and important biological process involved in various molecular functions and biological pathways. It also yields important biomarkers for clinical diagnoses. However, glycopeptide analysis is challenging due to low abundance, low ionization efficiency, and glycan heterogeneity. In the present study, a method based on hydrophilic interaction liquid chromatography (HILIC) was developed for the selective enrichment of glycopeptides using a novel metal-organic framework (MOF) nanocomposite (AuGC/ZIF-8). Dual functionalization with glutathione and cysteine has resulted in an ultra-hydrophilic MOF, with synergistic effects and lower steric hindrance, providing more affinity sites for the glycopeptide enrichment. Horseradish peroxidase (HRP) was used as a model glycoprotein, and AuGC/ZIF-8 was used to enrich glycopeptides prior to analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). AuGC/ZIF-8 displayed outstanding performance at enriching HRP glycopeptides, with high enrichment capacity (250 μg/mg), high selectivity in mixtures containing bovine serum albumin (BSA) (HRP-BSA (1∶200, mass ratio)), and high sensitivity at very low content (0.3 ng/μL). Thus this MOF holds promise for in-depth, comprehensive glycoproteomic and related analysis.Entities:
Keywords: glycopeptide; hydrophilic interaction liquid chromatography (HILIC); matrix-assisted laser desorption ionization time-of-flight-mass spectrometry (MALDI-TOF MS); metal-organic framework (MOF); post-translational modification (PTM); selective enrichment
Mesh:
Substances:
Year: 2021 PMID: 34227302 PMCID: PMC9403811 DOI: 10.3724/SP.J.1123.2020.11006
Source DB: PubMed Journal: Se Pu ISSN: 1000-8713
图1(a)AuGC/ZIF-8纳米复合材料的合成过程和(b)Cys、GSH双功能化金纳米簇
图2HRP酶解液(3 μg)用AuGC/ZIF-8富集 (a)前、(b)后的MALDI-TOF MS质谱图
经AuGC/ZIF-8富集后HRP酶解物中糖肽的详细信息
| No. | Glycan composition | Peptide sequence | |
|---|---|---|---|
| H1 | 1842.841 | [Xyl]1[Hex]3 [Fuc]1[HexNAc]2 | NVGLN#R |
| H2 | 2073.113 | [Xyl]1[Hex]3 [Fuc]1[HexNAc]2 | PN#VSNIVR |
| H3 | 2273.156 | [Xyl]1[Hex]2 [Fuc]1[HexNAc]2 | SILLDN#TTSFR |
| H4 | 2322.100 | [Hex]2 [HexNAc]2 | MGN#ITPLTGTQGQIR |
| H5 | 2541.128 | [Xyl]1[Hex]3[Fuc]1[HexNAc]2 | SSPN#ATDTIPLVR |
| H6 | 2611.216 | [Xyl]1[Hex]3[HexNAc]2 | MGN#ITPLTGTQGQIR |
| H7 | 2850.382 | [Fuc]1[HexNAc]1 | GLIQSDQELFSSPN#ATDTIPLVR |
| H8 | 3073.335 | [Fuc]1[HexNAc]1 | LHFHDCFVNGCDASILLDN#TTSFR |
| H9 | 3088.337 | [Xyl]1[Hex]3[Fuc]1[HexNAc] 2 | GLCPLNGN#LSALVDFDLR |
| H10 | 3321.343 | [Xyl]1[Hex]3[Fuc]1[HexNAc]2 | QLTPTFYDNSCPN#VSNIVR |
| H11 | 3354.298 | [Xyl]1[Hex]3[Fuc]1[HexNAc]2 | SFAN#STQTFFNAFVEAMDR |
| H12 | 3372.248 | [Xyl]1[Hex]3[Fuc]1[HexNAc]2 | SFAN#STQTFFNAFVEAM*DR |
| H13 | 3537.497 | [Hex]3[Fuc]1[HexNAc]2 | GLIQSDQELFSSPN#ATDTIPLVR |
| H14 | 3605.486 | [Xyl]1[Hex]3[Fuc]1[HexNAc]2 | NQCRGLCPLNGN#LSALVDFDLR |
| H15 | 3671.579 | [Xyl]1[Hex]3[Fuc]1[HexNAc]2 | GLIQSDQELFSSPN#ATDTIPLVR |
| H16 | 3894.496 | [Xyl]1[Hex]3[Fuc]1[HexNAc]2 | LHFHDCFVNGCDASILLDN#TTSFR |
| H17 | 4056.530 | [Xyl]1[Hex]3[HexNAc]2 | QLTPTFYDNSC(AAVESACPR)PN#VSNIVR-H2O |
| H18 | 4221.659 | [Xyl]1[Hex]3[Fuc]1[HexNAc]2 | QLTPTFYDNSC(AAVESACPR)PN#VSNIVR |
| H19 | 4982.884 | [Xyl]1[Hex]3[Fuc]1[HexNAc]2 or | LYN#FSNTGLPDPTLN#TTYLQTLR |
| [Xyl]1[Hex]3[Fuc]1[HexNAc]2 |
N#: N-linked glycosylation site.
图3(a)不同含量HRP酶解液和(b)不同质量比的HRP和BSA酶解液通过AuGC/ZIF-8富集后的MALDI-TOF MS质谱图